Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 3/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 5/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008512 | 0.88 | HTR2C (0.36) | HTR6SIGMAR1HTR2CHTR2BHDAC1 | |
| SCHEMBL2004244 | 0.85 | HTR6 (0.39) | HTR6SIGMAR1HTR2CPIM1PRKCI | |
| SCHEMBL2006358 | 0.84 | SIGMAR1 (0.43) | HTR6SIGMAR1HTR2CHTR2BHDAC1 | |
| SCHEMBL2006211 | 0.82 | SIGMAR1 (0.38) | HTR6SIGMAR1HTR2CHTR2BXIAP | |
| SCHEMBL2007117 | 0.82 | HTR6 (0.40) | HTR6HTR2CHTR2BPOLBHDAC1 | |
| SCHEMBL2008339 | 0.81 | HTR6 (0.39) | HTR6SIGMAR1HTR2CHTR2BXIAP | |
| SCHEMBL2010491 | 0.80 | PRKCI (0.35) | SIGMAR1PIM1PRKCI | |
| SCHEMBL2006785 | 0.78 | PRKCI (0.35) | HTR6SIGMAR1HTR2CHTR2BXIAP | |
| SCHEMBL2004679 | 0.77 | HTR6 (0.38) | HTR6SIGMAR1HTR2CHTR2BPIM1 | |
| SCHEMBL2012429 | 0.76 | HTR6 (0.36) | HTR6XIAPBIRC2PIM1PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| EP-2094677-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV Remynd (BE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | HTR6 2082/4885SIGMAR1 1998/4885HTR2C 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.